The majority of bladder cancers(BCs)are non-muscle invasive BCs(NMIBCs)and show the morphology of a conventional urothelial carcinoma(UC).Aberrant morphology is rare but can be observed.The classification and characte...The majority of bladder cancers(BCs)are non-muscle invasive BCs(NMIBCs)and show the morphology of a conventional urothelial carcinoma(UC).Aberrant morphology is rare but can be observed.The classification and characterization of histologic subtypes(HS)in UC in BC have mainly been described in muscle in-vasive bladder cancer(MIBC).However,the currently used classification is ap-plied for invasive urothelial neoplasm and therefore,also valid for a subset of NMIBC.The standard transurethral diagnostic work-up misses the presence of HS in NMIBC in a considerable percentage of patients and the real prevalence is not known.HS in NMIBC are associated with an aggressive phenotype.Conse-quently,clinical guidelines categorize HS of NMIBC as“(very)high-risk”tumors and recommend offering radical cystectomy to these patients.Alternative strategies for bladder preservation can only be offered to highly selected patients and ideally within clinical trials.Novel treatment strategies and biomarkers have been established MIBC and NMIBC but have not been comprehensively invest-igated in the context of HS in NMIBC.Further evaluation prior to implementation into clinical practice is needed.展开更多
Objective:Neoadjuvant chemotherapy followed by radical cystectomy is considered the standard of care for patients with muscle invasive bladder cancer.In the last decade,interest in neoadjuvant chemotherapy has slowly ...Objective:Neoadjuvant chemotherapy followed by radical cystectomy is considered the standard of care for patients with muscle invasive bladder cancer.In the last decade,interest in neoadjuvant chemotherapy has slowly shifted from methotrexate,vinblastine,doxorubicin and cisplatin regime to gemcitabine and cisplatin regime.There are many publications on gemcitabine and cisplatin regime in literature which cover different aspects of treatment.This review aims to summarise the findings published so far on gemcitabine and cisplatin regime and present it in a concise manner.Methods:A systematic literature review was conducted searching the PubMeddatabase in December 2016 using the medical subject heading(MeSH)with the terms gemcitabine,cisplatin,chemotherapy,muscle invasive bladder cancer,and neoadjuvant.All relevant studies were included and results were analysed.Results:A total of 13 studies were included which published between 2007 and 2015.These 13 studies comprised of 754 subjects suffering from muscle invasive bladder cancer.The proportion of male patients ranged from 60%to 86.4%and the median age ranged from 54.2 to 77.3 years in various studies.Complete pathological response(pT0)was seen in 30.0%of patients and pathological downstaging(<pT2)was seen in 48.67%of patients.Conclusion:As per latest guidelines,neoadjuvant chemotherapy is recommended for patients with muscle invasive bladder cancer.There is substantial pathological downstaging with low toxicity in patients of muscle invasive bladder cancer who receive neoadjuvant gemcitabine and cisplatin regime.展开更多
Dear Editor,Radical cystectomy(RC)remains the standard treatment for muscle-invasive bladder cancer[1].However,urinary diversion after RC can lead to a range of postoperative complications,including parastomal hernia,...Dear Editor,Radical cystectomy(RC)remains the standard treatment for muscle-invasive bladder cancer[1].However,urinary diversion after RC can lead to a range of postoperative complications,including parastomal hernia,incontinence,urinary retention,recurrent urinary tract infections,and metabolic disorders,significantly impacting patients'quality of life[2].Partial cystectomy(PC)is a bladdersparing alternative for patients who cannot accept RC and has been utilized in managing muscle-invasive bladder cancer since the last century.However,the application of PC has always been a subject of controversy in clinical practice due to the high recurrence rate.In a matched case-control analysis conducted by Knoedler et al.[3],38%of the patients experienced intravesical tumor recurrence,and 19%of the patients ultimately underwent RC.Another study in the Memorial Sloan-Kettering Cancer Center showed that 22 of 58 patients who received PC experienced superficial or advanced recurrence[4].展开更多
Fifty years after the introduction of Bacillus Calmette-Guérin(BCG),a live attenuated strain of Mycobacterium bovis[1],it is still the most effective and successful adjuvant immunotherapy of non-muscle invasive b...Fifty years after the introduction of Bacillus Calmette-Guérin(BCG),a live attenuated strain of Mycobacterium bovis[1],it is still the most effective and successful adjuvant immunotherapy of non-muscle invasive bladder cancer(NMIBC)[2].The guidelines of the European Association of Urology(EAU)suggest a 6-weekly induction phase followed by a maintenance schedule of BCG once weekly for 3 weeks and at 3,6,12,18,24,30,and 36 months for 1 to 3 years[2].展开更多
文摘The majority of bladder cancers(BCs)are non-muscle invasive BCs(NMIBCs)and show the morphology of a conventional urothelial carcinoma(UC).Aberrant morphology is rare but can be observed.The classification and characterization of histologic subtypes(HS)in UC in BC have mainly been described in muscle in-vasive bladder cancer(MIBC).However,the currently used classification is ap-plied for invasive urothelial neoplasm and therefore,also valid for a subset of NMIBC.The standard transurethral diagnostic work-up misses the presence of HS in NMIBC in a considerable percentage of patients and the real prevalence is not known.HS in NMIBC are associated with an aggressive phenotype.Conse-quently,clinical guidelines categorize HS of NMIBC as“(very)high-risk”tumors and recommend offering radical cystectomy to these patients.Alternative strategies for bladder preservation can only be offered to highly selected patients and ideally within clinical trials.Novel treatment strategies and biomarkers have been established MIBC and NMIBC but have not been comprehensively invest-igated in the context of HS in NMIBC.Further evaluation prior to implementation into clinical practice is needed.
文摘Objective:Neoadjuvant chemotherapy followed by radical cystectomy is considered the standard of care for patients with muscle invasive bladder cancer.In the last decade,interest in neoadjuvant chemotherapy has slowly shifted from methotrexate,vinblastine,doxorubicin and cisplatin regime to gemcitabine and cisplatin regime.There are many publications on gemcitabine and cisplatin regime in literature which cover different aspects of treatment.This review aims to summarise the findings published so far on gemcitabine and cisplatin regime and present it in a concise manner.Methods:A systematic literature review was conducted searching the PubMeddatabase in December 2016 using the medical subject heading(MeSH)with the terms gemcitabine,cisplatin,chemotherapy,muscle invasive bladder cancer,and neoadjuvant.All relevant studies were included and results were analysed.Results:A total of 13 studies were included which published between 2007 and 2015.These 13 studies comprised of 754 subjects suffering from muscle invasive bladder cancer.The proportion of male patients ranged from 60%to 86.4%and the median age ranged from 54.2 to 77.3 years in various studies.Complete pathological response(pT0)was seen in 30.0%of patients and pathological downstaging(<pT2)was seen in 48.67%of patients.Conclusion:As per latest guidelines,neoadjuvant chemotherapy is recommended for patients with muscle invasive bladder cancer.There is substantial pathological downstaging with low toxicity in patients of muscle invasive bladder cancer who receive neoadjuvant gemcitabine and cisplatin regime.
基金supported by Natural Science Foundation of Hubei Province(ZRMS2020002466 to Liu Z).
文摘Dear Editor,Radical cystectomy(RC)remains the standard treatment for muscle-invasive bladder cancer[1].However,urinary diversion after RC can lead to a range of postoperative complications,including parastomal hernia,incontinence,urinary retention,recurrent urinary tract infections,and metabolic disorders,significantly impacting patients'quality of life[2].Partial cystectomy(PC)is a bladdersparing alternative for patients who cannot accept RC and has been utilized in managing muscle-invasive bladder cancer since the last century.However,the application of PC has always been a subject of controversy in clinical practice due to the high recurrence rate.In a matched case-control analysis conducted by Knoedler et al.[3],38%of the patients experienced intravesical tumor recurrence,and 19%of the patients ultimately underwent RC.Another study in the Memorial Sloan-Kettering Cancer Center showed that 22 of 58 patients who received PC experienced superficial or advanced recurrence[4].
文摘Fifty years after the introduction of Bacillus Calmette-Guérin(BCG),a live attenuated strain of Mycobacterium bovis[1],it is still the most effective and successful adjuvant immunotherapy of non-muscle invasive bladder cancer(NMIBC)[2].The guidelines of the European Association of Urology(EAU)suggest a 6-weekly induction phase followed by a maintenance schedule of BCG once weekly for 3 weeks and at 3,6,12,18,24,30,and 36 months for 1 to 3 years[2].
